ALK 101
Alternative Names: ALK-101Latest Information Update: 08 Jul 2026
At a glance
- Originator Shanghai Allink Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 22 Apr 2026 Pharmacodynamic, pharmacokinetic and adverse event data from a preclinical trial in Solid tumour presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 28 Mar 2025 Preclinical trials in Colorectal cancer in China (Parenteral) (Shanghai Allink Biotherapeutics pipeline, March 2025)
- 28 Mar 2025 Preclinical trials in Non-small cell lung cancer in China (Parenteral) (Shanghai Allink Biotherapeutics pipeline, March 2025)